Supriya Lifescience Ltd

Supriya Lifescience Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results during a meeting held on August 13, 2026. The company submitted the results along with a limited review report from its statutory auditors, Kakaria and Associates LLP. The financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and other applicable accounting principles. The auditors confirmed that based on their review, nothing came to their attention to suggest material misstatements or non-disclosure of required information.

Supriya Lifescience's standalone Q1 FY27 (quarter ended June 30, 2026) revenue rose 30.8% YoY to ₹189.7 Cr (from ₹145.1 Cr), but standalone PAT fell 30.9% YoY to ₹24.0 Cr (from ₹34.8 Cr) — a classic case of top-line growth masking a sharp margin squeeze. Sequentially the picture is starker: revenue was down 31.4% and PAT down 67.6% versus the seasonally strong Q4 FY26 (₹276.5 Cr revenue, ₹74.2 Cr PAT), though Q4-to-Q1 sequential drops are typical for this business given its export-driven, lumpy order pattern. EPS came in at ₹2.99 versus ₹9.22 in Q4 FY26 and ₹4.32 a year ago. The compression sits squarely on the cost line. Cost of materials consumed jumped to 57.7% of revenue (from ~30% both YoY and QoQ), and even after netting off a large finished-goods inventory build, net material cost intensity still rose to 29.7% of sales from 21.9% a year ago. Other expenditure also crept up to 30.3% of revenue from 26.8% YoY. Total expenses absorbed 79.9% of revenue versus 69.2% a year ago, pulling operating margin (PBT + depreciation + finance cost, over revenue) down to 25.0% from 35.6% YoY and 35.3% QoQ — well below management's own FY27 guidance band of 33-35% EBITDA margin. Net profit margin fell to 12.7% from 23.6% YoY and 26.5% QoQ. On guidance, management had targeted ~20% annual FY27 revenue growth toward a ₹1,000 Cr full-year target with 33-35% EBITDA margins; this quarter's 30.8% YoY revenue growth runs ahead of that pace, but the margin miss means the quarter reads as missing the guided profitability band even as topline outpaces it. Against Street, a pre-result trailing-growth model (Univest) had pencilled in a YoY decline — revenue ~₹131 Cr and PAT ~₹27 Cr — so the actual revenue print is a sizeable beat, but PAT of ₹24.0 Cr still came in below that ₹27 Cr estimate, a modest miss on the bottom line. No management press release was available to cross-check the company's own framing of the quarter. Separately, note 3 to the results discloses that export goods were intercepted and held in Customs custody as of quarter-end yet already recognised as a sale since the shipment had reached Customs for export processing — a disclosure that lines up with the company's July 2026 announcement that a General Manager was arrested by Customs and remains in judicial custody, a live overhang investors should track alongside the margin trajectory.

Supriya Lifescience Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda item is to consider and approve the Unaudited Financial Results for the first quarter ended June 30, 2026. Concurrently, the company has closed its 'Trading Window' for designated persons and their immediate relatives from July 1, 2026, until 48 hours after the declaration of these financial results, in line with its Insider Trading Prevention Code.

Supriya Lifescience Ltd has disclosed that an investigation has been initiated against Mr. Sreekant Sreedharan, General Manager of Sales & Marketing, by the Special Investigation and Intelligence branch of the Customs Department. The officer has been granted judicial custody until July 17, 2026. The proceedings are related to alleged violations under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, for a procedural lapse concerning a single export transaction. The company stated that based on current information, the proceedings are not expected to have a material impact on its operations, financial position, or governance. Supriya Lifescience is monitoring the situation and obtaining legal advice.

Supriya Lifescience Ltd has issued an email communication to its shareholders detailing the dividend taxation provisions as per the Income Tax Act, 1961. The company will deduct tax at source (TDS) on the recommended final dividend of Re. 1.00 per equity share for FY 2025-26, subject to shareholder approval. The TDS rates will vary based on the shareholder's residential status and submitted documentation. Resident individual shareholders with aggregate dividend income not exceeding ₹10,000 will be exempt. Shareholders are urged to update their details with the RTA for accurate tax deduction.

Supriya Lifescience Ltd has announced the closure of its trading window for all insiders and designated persons, including their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, and will reopen 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The specific date for the Board Meeting to consider these results will be communicated separately.

Supriya Lifescience Ltd. announced strong financial results for Q4 FY26 and the full year FY26. For Q4 FY26, revenue surged 50.2% year-over-year to ₹276.53 crore, with Profit After Tax (PAT) at ₹74.23 crore. For the full fiscal year FY26, revenue from operations grew 18.9% YoY to ₹827.87 crore, and PAT increased 11.3% YoY to ₹209.12 crore. The anesthetic segment was the primary growth driver, contributing 54% of total revenues in FY26. Europe remained the largest market, and export contribution was strong at approximately 82% of FY26 revenues. The company also commercialized its Liquid Anesthetic product, improved capacity utilization to 74%, and strengthened its manufacturing and R&D infrastructure.

Supriya Lifescience Ltd's Board of Directors, in its meeting held on May 27, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1.00 per equity share (50% on the face value of ₹2 each), subject to shareholder approval at the upcoming Annual General Meeting. The meeting commenced at 03:45 p.m. and concluded at 06:00 p.m.

Supriya Lifescience Ltd announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results and recommended a final dividend of ₹1.00 per equity share (50% on the face value of ₹2 each), subject to shareholder approval at the upcoming Annual General Meeting. The auditor's report indicated an unmodified opinion on the standalone financial results.

Supriya Lifescience Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. They recommended a final dividend of ₹1.00 per equity share (50% on face value of ₹2), subject to shareholder approval at the upcoming Annual General Meeting. The board meeting commenced at 3:45 p.m. and concluded at 6:00 p.m.